CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of follicular lymphoma.
  
  LEARNING OBJECTIVES

  • Evaluate published research data and clinical investigator perspectives when designing an optimal approach to induction therapy for patients with newly diagnosed follicular lymphoma (FL) requiring active therapy.
  • Identify patient- and disease-specific factors that may portend poor response to initial chemoimmunotherapy, and consider this information in treatment decision-making for individuals with previously untreated FL.
  • Appreciate available data investigating rituximab/lenalidomide for patients with treatment-naïve and relapsed/refractory (R/R) FL, and optimally incorporate this approach into therapeutic algorithms.
  • Compare and contrast the data supporting the use of the commercially available PI3K inhibitors idelalisib, copanlisib, duvelisib and umbralisib, and use this understanding to optimally integrate these agents into the care of patients with R/R FL.
  • Recall key efficacy and safety data from clinical trials of approved and investigational chimeric antigen receptor T-cell therapies directed at CD19 for R/R FL, and identify patients who may be candidates for this approach.
  • Review the mechanism of action of, available data with and ongoing evaluation of bispecific antibodies targeting CD20 and CD3, and consider the potential role of these agents in the management of R/R FL.
  • Assess ongoing clinical trials evaluating other novel investigational approaches for newly diagnosed or R/R FL, and obtain consent from appropriate patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  John P Leonard, MD
  Richard T Silver Distinguished Professor of Hematology and Medical Oncology
  Senior Associate Dean for Innovation and Initiatives
  Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
  Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Miltenyi Biotec, Mustang Bio, Regeneron Pharmaceuticals Inc, Second Genome, Sutro Biopharma; Contracted Research: Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Clinical Professor of Medicine
  Division of Medical Oncology
  University of British Columbia
  Associate Editor, Blood
  Vancouver, British Columbia, Canada
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lundbeck, Merck, MorphoSys, Novartis, Pfizer Inc, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Seagen Inc, Takeda Pharmaceuticals USA Inc, Teva Oncology, Verastem Inc; Contracted Research: Teva Oncology.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Bristol-Myers Squibb Company and Genentech, a member of the Roche Group.
  
  Release date: February 2022
  Expiration date: February 2023